McKesson Sells 20% Stake in Medical-Surgical Solutions to Apollo for $7.4B

H.B. Fuller Acquires Advanced Medical Solutions Group for €715 Million

June 25, 2026

Healthcare Services

H.B. Fuller announced it has made a recommended cash offer to acquire Advanced Medical Solutions Group plc for an implied enterprise value of €715 million. AMS shareholders approved the proposed acquisition at special meetings, with the transaction expected to close by the end of calendar year, subject to remaining conditions and regulatory approvals.

Medallia Recapitalization and Ownership Transition Led by Blackstone, Apollo, and FS KKR

June 19, 2026

Cloud & SaaS

Medallia entered into a recapitalization agreement with its lenders that will reduce outstanding debt and provide $150 million of new capital. Upon completion, Medallia’s ownership will transition from Thoma Bravo to an investor group led by Blackstone, Apollo, and FS KKR Capital Corp.

Apollo Funds Completes Acquisition of Barnes Group for $3.6 Billion

January 27, 2025

Industrial Services

Funds managed by affiliates of Apollo Global Management (the Apollo Funds) completed an all-cash acquisition of Barnes Group, valuing Barnes at approximately $3.6 billion. Barnes shareholders received $47.50 per share, and Barnes was delisted from the NYSE to become privately held.

Boston Scientific to Acquire Apollo Endosurgery for $615 Million

November 30, 2022

Medical Devices

Boston Scientific Corporation has entered into a definitive agreement to acquire Apollo Endosurgery for $615 million in cash (approximately $10 per share). The deal expands Boston Scientific’s endoluminal surgery (ELS) capabilities and adds an adjacency into the endobariatric market.

McKesson Signs Agreement to Acquire Rx Savings Solutions

September 19, 2022

Healthcare Services

McKesson Corporation has signed a definitive agreement to acquire Rx Savings Solutions (RxSS), a prescription price transparency and benefit insight company focused on affordability and medication adherence for health plans and large self-funded employers. The transaction is valued up to $875 million ($600 million upfront plus up to $275 million contingent on RxSS performance through calendar year 2025) and is expected to close in the second half of fiscal 2023, subject to customary regulatory approvals. Following closing, RxSS will become part of McKesson’s Prescription Technology Solutions business.

Provepharm Life Solutions Acquires Apollo Pharmaceuticals USA

December 2, 2020

Pharmaceuticals

Provepharm Life Solutions has acquired Apollo Pharmaceuticals USA Inc., a Florida-based commercial specialist in sterile injectable products for hospitals. The acquisition strengthens Provepharm's U.S. commercial platform and adds Apollo's four registered products, enabling faster U.S. growth and streamlined hospital-focused sales operations.